News Related to Synthetic Lethality

Related coverage linked through entity extraction aliases.

Lantern Pharma Announces FDA Orphan Drug Designation for LP-284 and USPTO Patent Allowance for LP-184

Jul 24, 2026

Lantern Pharma's LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, while the USPTO allowed a patent for biomarker-guided use of LP-184 in multiple cancers. LP-284 showed a complete metabolic response in a Phase 1 DLBCL patient, and LP-184 demonstrated a 45% disease control rate in advanced solid tumors.

PARP inhibitors remain strongest in BRCA-mutant tumors as labels narrow

Apr 22, 2026

PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.